Clinical trials: Congenital Cmv

Cytomegalovirus Infection

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

• Completed
• Age: 18 to 40 years
• Phase 2
• Results posted

This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.

Trial name

NCT04232280

Testing

mRNA-1647

Where

9 sites in United States

Volunteers

315 people, healthy volunteers welcome

Sponsor

ModernaTX, Inc.